Sign in
Taking people in SpainPhase 4

Compares an electric-current bladder treatment with mitomycin C against BCG in bladder cancer

Compares mitomycin C given with electric current to BCG in adults with high-grade bladder cancer.

Key facts

Who runs it
Presurgy S.L.
Where
A Coruña, Barakaldo, Barcelona, Cadiz, Coslada, Donostia, Logroño, Madrid, Murcia, Oviedo, Pamplona, San Cristóbal de La Laguna, Santander, Valencia, Valladolid, and Vitoria, SpainSee the 20 sites
Registry title
Study to evaluate the efficacy and safety of supportive mitomycin C administered via electric current in the treatment of non-muscle invasive bladder cancer versus the standard immunotherapy.
Status
Recruiting
Phase
Phase 4
People taking part
230 people, planned
Started
15 Dec 2021
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
9 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a first high-grade non-muscle invasive bladder cancer (stage Ta or T1) whose tumour was fully removed. It compares MMC given with electric current (EMDA-MMC) to BCG.

Age
Older than 18 years, with a life expectancy of 5 years or more.
Sex
All sexes can join.
Disease stage
First (primary) high-grade non-muscle invasive bladder cancer, stage Ta or T1, one or several tumours. Biopsies of the bladder must be negative for Tcis.
Earlier treatment
The tumour must have been fully removed by TUR, with muscle present in the sample. A repeat TUR within the first 6 weeks is needed when guidelines call for it, and in all T1 cases.

Main reasons for not taking part

  • Tumour of stage T2 or higher, or spread to lymph nodes or other organs
  • Pregnant women
  • Earlier bladder tumour or earlier pelvic radiotherapy
  • Allergic reaction to BCG or MMC in the past
  • Pacemaker or defibrillator (DIC), or carcinoma in situ (Tcis) alone or with a papillary tumour

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Patients older than 18 years and life expectancy ≥ 5 years
  • Patients able to give informed consent for the study
  • Patients with primary non-muscle infiltrating urothelial non-muscle metamorphosed (NMIBC), uni- or multi-focal, stages Ta and T1, High Grade (2004 WHO), including old G2 High Grade and all G3
  • Patients treated with optically complete TUR of the tumor and, when indicated by clinical guidelines, RE-RTU that must be performed within the first 6 weeks
  • Negative bladder random biopsies for Tcis
  • Presence of own muscle in the TUR and / or in the RE-RTU
  • RE-RTU in all cases of T1 and also in Ta tumors when the initial TUR is incomplete or with absence of muscle in the sample

Who cannot take part

  • Previous history of bladder tumors
  • Antecedents of pelvic radiotherapy (bladder, prostate, rectum, vagina, uterus)
  • Patients with stage T1 who have not received RE-RTU
  • Relative contraindications for the use of the EMDA system - Urethral stricture. - Giant prostatic lobe with bladder neck occlusion. - Psychosis - Alcoholism - Active untreated urinary infection
  • Patients with a history of allergic reactions to BCG or MMC
  • Patients unable to give informed consent for their participation in the study
  • Stage tumors ≥T2
  • cN + and / or cM + tumors
  • Pregnant women
  • Patients with pacemakers or DICs
  • Absence of own muscle in the sample (neither in RTU nor in RE-RTU)
  • Patients with Tcis isolated or associated with papillary tumor
  • Presence of squamous cell carcinoma of the bladder or bladder adenocarcinoma

Where in Spain

  • Complexo Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
  • Hospital Universitario de CrucesBarakaldo, SpainTaking people
  • Fundació PuigvertBarcelona, SpainTaking people
  • Hospital Universitario Puerta del MarCadiz, SpainTaking people
  • Hospital Universitario Del HenaresCoslada, SpainTaking people
  • Hospital Universitario DonostiaDonostia, SpainTaking people
  • Hospital San PedroLogroño, SpainTaking people
  • Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
  • Hospital Universitario La PazMadrid, SpainTaking people
  • Hospital Universitario Ramón y CajalMadrid, SpainTaking people
  • Hospital General Universitario Morales MeseguerMurcia, SpainTaking people
  • University Clinical Hospital Virgen De La ArrixacaMurcia, SpainTaking people
  • Hospital Universitario Central De AsturiasOviedo, SpainTaking people
  • Hospital Universitario de NavarraPamplona, SpainTaking people
  • Hospital Universitario de CanariasSan Cristóbal de La Laguna, SpainTaking people
  • Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
  • Fundación Instituto Valenciano de OncologíaValencia, SpainTaking people
  • Hospital 9 De Octubre S.A.Valencia, SpainTaking people
  • Hospital Universitario Rio HortegaValladolid, SpainTaking people
  • Hospital Universitario ArabaVitoria, SpainTaking people

About the trial

What the trial wants to find out

To evaluate the efficacy of the adjuvant with EMDA-MMC (induction x6 weekly instillations and 1 year of maintenance) compared with the BCG standard (induction x6 weekly instillations and 1 year of maintenance) in the adjuvant treatment of High Grade NMLCC.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Multicenter clinical trial with medical device associated with a drug in an authorised therapeutic use for the treatment of CVNMI evaluating the efficacy and tolerability of the adyuvant treatment with EMDA-MMC versus standard BCG in patients with high grade CVNMI
Plain-language title
Compares an electric-current bladder treatment with mitomycin C against BCG in bladder cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
9 October 2025